Pfizer Australia and MSD
will co-promote MSD’s DPP4
inhibitor (sitagliptin) franchise,
with representatives from both
companies promoting Januvia
(sitagliptin), Janumet (sitagliptin/
metformin) and soon to be PBS
listed Janumet XR (sitagliptin/
metformin extended release).
This follows the global
arrangement between the
companies, announced in April last
year, to develop and commercialise
Pfizer’s oral sodium glucose
cotransporter inhibitor, which has
started phase III trials.
Pfizer head of marketing James
Price said it allowed the companies
to start their collaboration in
the diabetes space earlier, giving
experience in working together.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.